Expanding its life sciences patent litigation group in New York, McGuireWoods has hired a trio of partners from Baker & Hostetler who specialize in guiding companies through disputes related to intellectual property protections on branded and generic drugs.

The three lateral hires, Benjamin Hsing, Wanda French-Brown and Irene Hudson, have worked alongside each other for about three years and started at McGuireWoods on Wednesday, they said in an interview. As a group, they have experience handling litigation stemming from abbreviated new drug applications (ANDAs)—the process set out under the Hatch-Waxman Act that regulates when and how generic drugs can come to market.

Benjamin Hsing, McGuireWoods

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]